News

Bridging Gaps and Investing in Change

January 03, 2024

European bio/pharma companies have no choice but to invest and adapt to the evolving industry needs.

Frontrunners in Molecular Glues

January 03, 2024

Novel molecular glues are transforming targeted protein degradation.

Bringing Collaboration to the Horizon Once More

January 03, 2024

UK scientists are once again able to participate in the Horizon European research programme thanks to a deal struck in 2023.

AstraZeneca to Acquire Icosavax in Deal Valued at Approximately $1.1 Billion

January 02, 2024

With the acquisition, AstraZeneca will gain a potential RSV and hMPV combination vaccine.

Finalizing the European Health Data Space

January 02, 2024

The EHDS aims to increase access to health data, but how will it impact pharma?

Unlucky for Some

January 02, 2024

Clarivate has released its 2024 Drugs to Watch report, highlighting 13 therapies with great potential.

The Decline and Fall of the Clinician–Scientist

December 29, 2023

Clinician-Scientists are vital innovation spark plugs, accounting for 40% of Nobel awards in Physiology or Medicine, and two thirds of Big Pharma CSOs.

Replay Signs Exclusive Licensing Agreements with NIH and Miltenyi Biotec for Cell Therapy Development and Manufacturing

December 29, 2023

Through Syena, its oncology-focused product company, Replay will develop and manufacture T-cell receptor and natural killer cell therapies with the NIH and Miltenyi Biotec.

Körber and Franz Ziel Tighten Ties

December 28, 2023

Is increasing molecular diversity pushing manufacturing ecosystem consolidation toward turnkey solutions?

Tome brings $213 Million to the Programmable Genome Editing Party

December 28, 2023

Tome Bioscience is facilitating the transition in biology from the editing phase to the cut-and-paste phase.